10-oxo-trans-8-decenoic acid | 69152-89-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 10-oxo-trans-8-decenoic acid
• 英文别名: (8E)-10-oxo-8-decenoic acid；10-Oxodec-8-enoic acid；10-oxo-8-decenoic acid；9-carboxy-2-trans-nonenal；trans-10-Oxodec-8-ensaeure；(E)-10-Oxo-8-decenoic acid；(E)-10-oxodec-8-enoic acid
• CAS: 69152-89-2
• 化学式: C₁₀H₁₆O₃
• 分子量: 184.235
• InChiKey: YUAQBOMIASXPQW-FNORWQNLSA-N

物化性质

• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）
• 物理描述：
  Solid
• 熔点：
  49-51°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  环戊二烯 、 10-oxo-trans-8-decenoic acid 生成 7-[(1S,2S,3R,4R)-3-formyl-2-bicyclo[2.2.1]hept-5-enyl]heptanoic acid
  参考文献：
  名称：

  SMITH J. R. L.; NORMAN R. O. C.; STILLINGS M. R., TETRAHEDRON, 1978, 34, NO 9, 1381-1383

  摘要：

  DOI：
• 作为产物：
  描述：

  10-Hydroperoxy-8,12-octadecadienoic acid 以65%的产率得到
  参考文献：
  名称：

  LABEQUE R.; MARNETT L. J., J. AMER. CHEM. SOC., 109,(1987) N 9, 2828-2829

  摘要：

  DOI：

文献信息

• Factors affecting the endo : exo ratio in diels-alder reactions of cyclopentadiene
  作者：John R. Lindsay Smith、Richard O.C. Norman、Michael R. Stillings

  DOI：10.1016/0040-4020(78)88334-3

  日期：1978.1

  The ratio of endo-CHO:exo-CHO in the Diels-Alder addition of a trans-αβ-unsaturated aldehyde to cyclopentadiene can be changed from 1:2 to 8:1, depending on temperature and BF3-catalysis.

  反式-αβ-不饱和醛与环戊二烯的Diels-Alder加成中内-CHO：外-CHO的比例可根据温度和BF 3-催化而从1：2变为8：1 。
• Substituted bicyclo (2,2,1)heptanes and bicyclo (2,2,1) hept-2-enes and their pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0013607A1

  公开（公告）日：1980-07-23

  Novel bicyclo [2,2,1] heptanes and hept-2Z-enes are substituted at the 5-position by a 6-carboxyhex-2-enyl group or a modification thereof, and at the 6-position by an aldoxime or ketoxime group which is O-substituted by an aliphatic hydrocarbon residue, an aromatic residue, or an aliphatic hydrocarbon residue substituted directly orthrough an oxygen or sulphur atom by an aromatic residue. Such compounds may be prepared by the action of an oximating agent on an intermediate which is substituted at the 6-position by an aldehydic or ketonic carbonyl group. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.

  新型双环[2,2,1]庚烷和庚-2Z-烯在 5 位被 6-羧基己-2-烯基或其改性物取代，在 6 位被醛肟基或酮肟基取代，该醛肟基或酮肟基被脂肪烃残基、芳香族残基或直接通过氧原子或硫原子被芳香族残基取代的脂肪烃残基 O 取代。此类化合物可通过氧化剂对中间体的作用制备，中间体的 6 位被醛基或酮基羰基取代。这些化合物具有药物组合物的使用价值，特别是在抑制血栓素活性方面。
• Prostaglandins
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0043292A2

  公开（公告）日：1982-01-06

  Novel compounds have a formula (I) wherein represents a bicyclo (2,2,1) hept-2Z-ene, bicyclo (2,2,1) heptane, 7-oxabicyclo (2,2,1) hept-2Z-ene, 7-oxabicyclo (2,2,1) heptane, bicyclo (2,2,2) oct-2Z-ene or bicyclo (2,2,2) octane substituted at the 5-position by the group R1 and at the 6-position by the group C(R2)=NR, a 6,6-dimethyl-bicyclo (3,1,1) heptane substituted at the 5- position by the group R' and at the 6-position by the group C(R2)=NR or at the 5-position by the group C(R2)=NR and at the 6-position by the group R1, a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R1 and at the 5-position by the group C(R2)=NR, or a 1-hydroxycyclopentane substituted at the 2-position by the group R1 and at the 2-position by the group C(R2)=NR, R1 is a 6-carboxyhex-2-enyl group or a modification thereof as defined herein, R2 is hydrogen, an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R is a group -OR3, -OR4, -A-R3 or -N=R5 in which A is -NH-, -NH.CO-, -NH.CO.CH2N(R6)-, -NH.SO2-, -NH.CO.NH or -NH.CS.NH- and wherein R3 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, R4 is an aliphatic hydrocarbon group which is substituted through an oxygen atom by an aliphatic hydrocarbon group which is itself substituted by an aromatic group, R5 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R6 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, with the proviso that when R is a group -OR3, -NH.COR3 or-NH.CO.NHR3 then excludes bicyclo (2,2,1) hept-2Z-enes and bicyclo (2,2,1) heptanes. The compounds are of value for use in phar. maceutical compositions particularly in the context of the inhibition of thromboxane activity.

  新型化合物具有式 (I) 其中 代表在 5 位被基团 R1 取代、在 6 位被基团 C(R2)=NR 取代的双环(2,2,1)庚-2Z-烯、双环(2,2,1)庚烷、7-氧杂双环(2,2,1)庚烷、双环(2,2,2)辛-2Z-烯或双环(2,2,2)辛烷、在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR 取代的 6,6-二甲基双环(3,1,1)庚烷，或在 5 位被基团 C(R2)=NR 取代、在 6 位被基团 R1 取代的 6,6-二甲基双环(3,1,1)庚烷、在 4 位被基团 R1 取代且在 5 位被基团 C(R2)=NR 取代的环己-1-烯或环己烷，或在 2 位被基团 R1 取代且在 2 位被基团 C(R2)=NR 取代的 1-羟基环戊烷、R1 是本文定义的 6-羧基己-2-烯基或其改性物，R2 是氢、脂肪族烃基或直接或通过氧原子或硫原子被芳香族基取代的脂肪族烃基，R 是基团-OR3、-OR4、-A-R3 或-N=R5，其中 A 是-NH-、-NH.CO-、-NH.CO.CH2N(R6)-、-NH.SO2-、-NH.CO.NH 或 -NH.CS.其中 R3 是直接或通过氧原子或硫原子被芳香基团取代的脂肪烃基团、芳香基团或脂肪烃基团，R4 是通过氧原子被本身被芳香基团取代的脂肪烃基团，R5 是脂肪烃基团、R6是氢、脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基，但当R是-OR3、-NH.COR3或-NH.CO.NHR3，则 不包括双环(2,2,1)庚-2Z-烯和双环(2,2,1)庚烷。这些化合物在医药组合物中具有使用价值，特别是在抑制血栓素活性方面。
• Prostaglandin intermediates
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0111955A1

  公开（公告）日：1984-06-27

  Novel compounds have a formula (I) wherein represents a bicyclo [2,2,1] hept-2Z-ene, bicyclo [2,2,1] heptane, 7-oxabicyclo [2,2,1] hept-2Z-ene, 7-oxabicyclo [2,2,1] heptane, bicyclo [2,2,2] oct-2Z-ene or bicyclo [2,2,2] octane substituted at the 5-position by the group R' and at the 6-position by the group C(R2)=NR, a 6,6-dimethyl-bicyclo [3,1,1] heptane substituted at the 5-position by the group R' and at the 6-position by the group C(R2)=NR or at the 5-position by the group C(R2)=NR and at the 6-position by the group R', a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R1 and at the 5-position by the group C(R2)=NR, or a 1-hydroxycyclopentane substituted at the 2-position by the group R1 and at the 2-position by the group C(R2)=NR, R1 is a 6-carboxyhex-2-enyl group or a modification thereof as defined herein, R2 is hydrogen, an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R is a group -OR3, -OR4, -A-R3 or -N=R5 in which A is -NH-, -CH.CO-, -NH.CO.CH2N(R6)-, -NH.S02-, -NH.CO.NH or -NH.CS.NH-and wherein R3 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, R4 is an aliphatic hydrocarbon group which is substituted through an oxygen atom by an aliphatic hydrocarbon group which is itself substituted by an aromatic group, R5 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R6 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, with the proviso that when R is a group -OR3, - NH.COR3 or -NH.CO.NHR3 then excludes bicyclo [2,2,1] hept-2Z-enes and bicyclo [2,2,1] heptanes. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.

  新型化合物具有式 (I) 其中 代表在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR.取代的双环[2,2,1]庚-2Z-烯、双环[2,2,1]庚烷、7-氧杂双环[2,2,1]庚烷、双环[2,2,2]辛-2Z-烯或双环[2,2,2]辛烷、在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR 取代的 6,6-二甲基双环[3,1,1]庚烷，或在 5 位被基团 C(R2)=NR 取代、在 6 位被基团 R'取代的 6,6-二甲基双环[3,1,1]庚烷、在 4 位被基团 R1 取代、在 5 位被基团 C(R2)=NR 取代的环己-1-烯或环己烷，或在 2 位被基团 R1 取代、在 2 位被基团 C(R2)=NR 取代的 1-羟基环戊烷、R1 是本文定义的 6-羧基己-2-烯基或其改性物，R2 是氢、脂肪族烃基或直接或通过氧原子或硫原子被芳香族基取代的脂肪族烃基，R 是基团-OR3、-OR4、-A-R3 或-N=R5，其中 A 是-NH-、-CH.CO-、-NH.CO.CH2N(R6)-、-NH.S02-、-NH.CO.NH 或 -NH.CS.其中 R3 是脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基；R4 是通过氧原子被脂肪族烃基取代的脂肪族烃基，该脂肪族烃基本身被芳香族基团取代；R5 是脂肪族烃基、R6是氢、脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基，但当R是-OR3、-NH.COR3或-NH.CO.NHR3，则 不包括双环[2,2,1]庚-2Z-烯和双环[2,2,1]庚烷。这些化合物具有药物组合物的使用价值，特别是在抑制血栓素活性方面。
• Production of food flavor-acceptable jasmonic acid and methyl jasmonate by Diplodia gossypina
  申请人：INTERNATIONAL FLAVORS & FRAGRANCES INC.

  公开号：EP1118672A2

  公开（公告）日：2001-07-25

  Described is a bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate, as well as a novel jasmonic acid isomer produced thereby and organoleptic uses thereof. The process yields at least 5% of the "cis" isomer defined according the structure: (wherein R is hydrogen or methyl) or at least 5% of the "cis" isomer defined according to the structure: (wherein R is hydrogen or methyl). Compositions containing at least 98% of the isomer having the structure: with an optical rotation (α20D) of +58° are novel. Compositions containing at least 98% of the isomer having the structure: with an optical rotation (α20D) of +58° are also novel. The process of our invention comprises the cultivation under aerobic condition of one or more specific strain of Diplodia gossypina in a nutrient medium followed either by (1) isolation of the jasmonic acid product or (2) esterification of the jasmonic acid to form methyl jasmonate followed by the isolation of the methyl jasmonate and novel products produced by such process.

  描述了一种高产生产可接受食品风味的茉莉酸和茉莉酸甲酯的生物工艺，以及由此生产的一种新型茉莉酸异构体及其感官用途。该工艺可获得至少 5%的按以下结构定义的 "顺式 "异构体： (其中 R 为氢或甲基）或至少 5%根据以下结构定义的 "顺式 "异构体： (其中 R 为氢或甲基）。含有至少 98%具有以下结构的异构体的组合物： 旋光度 (α20D) 为 +58° 的异构体的组合物是新颖的。含有至少 98%具有以下结构的异构体的化合物 光学旋转（α20D）为 +58° 的异构体的含量至少为 98% 的组合物也是新颖的。本发明的工艺包括在有氧条件下，在营养培养基中培养一株或多株Diplodia gossypina的特定菌株，然后(1)分离茉莉酸产物或(2)将茉莉酸酯化形成茉莉酸甲酯，然后分离茉莉酸甲酯和由该工艺产生的新型产物。